Key Highlights
- Nuvation rebounded by 12.05 percent on Wednesday to finish at $8.37 apiece following the stellar results of its phase 2 study for the efficacy of Safusidenib to treat of a type of brain tumor.
- In an updated report on the same day, Nuvation Bio Inc.
- (NYSE:NUVB) said that the study met its primary endpoint, having demonstrated an objective response rate of 44.4 percent.
- The study evaluated 27 patients with IDH1-mutant grade 2 gliomas who had no prior anticancer therapy except for resection or biopsy.
- Side effects were also mostly mild to moderate and considered manageable.